RxDoctor Payments Data

Hollynn Knight, DO

Internal Medicine · Clairton, PANPI 1699201426

Payments from drug & device makers

$17,025in general payments, 2019–2025

Across 1,000 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • GSK$1K
  • Pfizer$1K
  • Amarin Pharma, Inc.$977
  • plus $7K from 33 others

What the payments were for

  • Food & beverage$16,92999%
  • Education$971%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$17,025 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$66,544
Medicare patients
163
Services billed
669

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban98$104,743
RybelsusSemaglutide60$71,906
JardianceEmpagliflozin61$56,575
OzempicSemaglutide41$50,279
MounjaroTirzepatide38$38,907
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$23,153
XareltoRivaroxaban18$22,233
TradjentaLinagliptin29$21,982
Breo ElliptaFluticasone/Vilanterol21$13,521
EntrestoSacubitril/Valsartan15$11,920
JanuviaSitagliptin Phosphate17$11,395
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$4,382
Levothyroxine Sodium415$3,961
Atorvastatin Calcium475$3,695
AbrysvoRsv Vacc, Pref A And Pref B/Pf11$3,351

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$2,388$122,185101 claims
PfizerEliquis, Abrysvo$1,233$108,094109 claims
Boehringer IngelheimJardiance, Tradjenta$947$78,55790 claims
Lilly USA, LLCMounjaro$1,365$38,90738 claims
GSKTrelegy Ellipta, Breo Ellipta$1,241$36,67348 claims
Johnson & JohnsonXarelto$254$22,23318 claims
NovartisEntresto$371$11,92015 claims
MerckJanuvia$180$11,39517 claims
AbbVieSynthroid$2,790$2,90562 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Clairton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →